Tesamorelin

Mechanism of action in research models

GHRHR agonism: like all GHRH analogues, Tesamorelin activates the GHRH receptor through Gs-cAMP-PKA signalling on pituitary somatotroph cells. The full-length GHRH(1-44) backbone provides all residues that contribute to GHRHR binding affinity, while the trans-3-hexenoic-acid N-terminal modification provides DPP-IV resistance without compromising receptor affinity.

Pulsatile GH secretion: Tesamorelin stimulates pulsatile GH release from somatotrophs consistent with physiological GH rhythmicity, rather than the continuous elevation produced by CJC-1295 with DAC. Pulsatility preservation is mechanistically important for research examining GH-dependent gene expression, IGF-1 production rhythms, and downstream metabolic effects that differ qualitatively between pulsatile and continuous GH exposure.

IGF-1 axis activation: through GH-receptor stimulation on hepatocytes, the GH secreted in response to Tesamorelin induces IGF-1 synthesis and secretion. In preclinical models, Tesamorelin-induced GH increases translate to measurable IGF-1 elevations over days to weeks.

Visceral-adipose-tissue (VAT) research: a distinctive research application — GH is lipolytic in visceral fat depots, and Tesamorelin’s GH-releasing activity has been shown to reduce visceral adipose tissue accumulation in multiple models. The proposed mechanism involves GH-mediated upregulation of hormone-sensitive lipase and lipolysis in intra-abdominal fat.

Triglyceride and lipid metabolism: documented reductions in circulating triglycerides in research models attributed to GH-mediated increases in lipoprotein-lipase activity and triglyceride clearance.

Research background and peer-reviewed literature

Tesamorelin was developed by Theratechnologies and extensively characterised in human clinical research. Falutz et al. published Phase-3 data in NEJM (2007) demonstrating significant reductions in trunk fat (measured by CT cross-sectional area) in HIV-infected patients with lipodystrophy versus placebo — establishing Tesamorelin as the first GHRH analogue proven to selectively reduce visceral adipose tissue in a controlled study. Subsequent mechanistic research has used Tesamorelin to study GH-mediated visceral-fat reduction, including GH-receptor signalling in visceral vs subcutaneous preadipocytes.

Reconstitution and storage protocol

1. Allow vial to equilibrate to room temperature before opening.
2. Reconstitute with bacteriostatic water or sterile PBS. Tesamorelin is water-soluble at physiological pH; 0.5–1 mg/mL is a practical research concentration.
3. Add diluent slowly along the vial wall; swirl gently to dissolve.
4. Filter through 0.22 μm for sterile cell-culture applications.

Storage: lyophilized at −20 °C, sealed, desiccated, light-protected (stable 24+ months). Reconstituted at 4 °C for up to 28 days; aliquot at −80 °C for extended storage.